Menopause
Clinical Snapshot
Menopause is the permanent cessation of menstruation from loss of ovarian follicular estrogen production, confirmed retrospectively after 12 consecutive months of amenorrhea; the average age of natural menopause in Canada is about 51, though it can occur naturally anywhere from age 40 to 58.[1] Perimenopause (the menopausal transition) begins with a change in menstrual cycle length and ends at the final menstrual period, often producing symptoms indistinguishable from menopause itself. Early menopause is menopause before age 45 and premature menopause (premature ovarian insufficiency) is before age 40 — both carry an extended duration of estrogen deficiency and warrant hormone therapy until at least the average age of natural menopause. Vasomotor symptoms (hot flashes, night sweats) are the most commonly reported complaint and can begin years before the final menstrual period, while genitourinary symptoms (vaginal dryness, dyspareunia, urinary irritative symptoms) tend to appear later and, unlike vasomotor symptoms, do not resolve on their own with time. This chapter covers three parallel treatment tracks — systemic menopausal hormone therapy, non-hormonal prescription options, and local vaginal estrogen for genitourinary symptoms — and the specific clinical rules (uterine status, timing/window of opportunity, route selection, and contraindications) that determine which track and which agent a given patient should start on.[2]
Recognize the Condition
The menopausal transition
Stages of the menopausal transition
Perimenopause
Begins with a change in menstrual cycle length or regularity and ends at the final menstrual period. Vasomotor and other symptoms are often already present and can be difficult to distinguish from menopause itself.
Menopause
The point marking 12 consecutive months of amenorrhea due to loss of ovarian estrogen production — diagnosed retrospectively, not predicted in advance.
Postmenopause
The remainder of life after menopause. Vasomotor symptoms typically persist for several years into this stage before resolving, while genitourinary symptoms tend to persist or worsen indefinitely without treatment.
Vasomotor symptoms
Hot flashes and night sweats — a sudden sensation of heat, often with flushing, sweating, and palpitations, lasting a few minutes. Onset relative to the final menstrual period varies widely; some patients report vasomotor symptoms up to 10 years before their final period. On average, vasomotor symptoms last 7-8 years in total and persist for several years after the final menstrual period.[1] Sleep disruption, mood changes (irritability, anxiety, depressive symptoms), headaches, and joint pain are also commonly reported during the transition and can compound the impact of vasomotor symptoms on quality of life.
Genitourinary syndrome of menopause (GSM)
Vaginal dryness, itching, irritation, and dyspareunia, often combined with urinary symptoms (recurrent urinary tract infection, dysuria, urinary frequency and urgency) from estrogen-deficient genital and lower urinary tract tissue. Patients often report these symptoms starting later than vasomotor symptoms, and — unlike hot flashes — genitourinary symptoms do not improve on their own over time and typically require ongoing treatment to stay controlled.[3][4]
Risk Factors
- Factors associated with earlier (before age 45) or premature (before age 40) menopause: bilateral oophorectomy, pelvic radiation or chemotherapy, smoking, and a family history of early menopause.
- Factors associated with more severe or longer-lasting vasomotor symptoms: younger age at symptom onset, higher body mass index, smoking, lower education level, and depressive or anxiety symptoms.
- Factors that increase venous thromboembolism and cardiovascular risk with systemic hormone therapy specifically (relevant to candidacy and route selection, not to menopause itself): obesity, smoking, immobility, personal or family history of venous thromboembolism, uncontrolled hypertension, and migraine with aura.
- Factors increasing osteoporosis and fracture risk after menopause: early or premature menopause, low body weight, smoking, sedentary lifestyle, glucocorticoid use, and a personal or family history of fragility fracture.
Red Flags & Refer
Menopause itself is not an emergency, but several presentations that can accompany it require urgent investigation independent of, and before, any decision about hormone therapy.
- Any unexplained or unscheduled postmenopausal vaginal bleeding — always requires endometrial sampling to rule out endometrial carcinoma before or independent of starting or continuing menopausal hormone therapy; never attribute it to hormones without investigation.
- New breast findings on self- or clinical exam — a new lump, focal pain, skin changes, or nipple discharge — need prompt breast assessment regardless of hormone therapy status.
- Signs of venous thromboembolism while on hormone therapy — unilateral leg swelling, warmth, or pain, or sudden shortness of breath or chest pain — require stopping therapy and urgent assessment.
- Signs of stroke or transient ischemic attack while on hormone therapy — sudden weakness or numbness, vision changes, slurred speech, or a severe sudden headache — require stopping therapy and emergency assessment.
- Signs of active liver disease (jaundice, right upper quadrant pain) while on hormone therapy or fezolinetant — hold therapy and investigate liver function urgently.
- Symptoms suggesting an alternative endocrine cause of flushing or menstrual change rather than menopause — hyperthyroidism, carcinoid syndrome, or pheochromocytoma — warrant the corresponding work-up rather than empiric menopause treatment.
- Suspected premature ovarian insufficiency (amenorrhea with menopausal symptoms before age 40) — refer for confirmatory testing and specialist management given the long-term cardiovascular and bone consequences of untreated prolonged estrogen deficiency.
Assessment & Diagnosis
Confirming the diagnosis
In a patient over 45 years of age who has not had a menstrual period for 12 months, the diagnosis of menopause is made clinically — FSH and estradiol measurement are not required and do not change management. In a patient over 45 with vasomotor symptoms and irregular periods, perimenopause can similarly be diagnosed on symptoms alone.[1]
Reserve hormonal testing for a patient under 45 with menopausal symptoms and uncertain ovarian function, or a patient under 40 in whom premature ovarian insufficiency is suspected: confirm with a serum FSH persistently above 40 IU/L on 2 occasions 4-6 weeks apart.[1]
Differential diagnoses to consider
Before attributing vasomotor or menstrual-cycle symptoms to menopause, consider and rule out other causes when the clinical picture is atypical:
- Hyperthyroidism.
- Carcinoid syndrome.
- Pheochromocytoma.
- Other causes of secondary amenorrhea in a younger patient (e.g., pregnancy, hypothalamic amenorrhea, hyperprolactinemia).
Health maintenance screening at the menopause visit
- Blood pressure, breast examination, and cervical cytology as part of the initial evaluation.
- Mammography every 2-3 years for patients over 50; consider earlier screening in patients at higher breast cancer risk (e.g., strong family history).
- Bone mineral density screening in patients at high osteoporosis risk (see Risk Factors).
- Cardiovascular risk assessment (e.g., Framingham 10-year risk score) every 3-5 years for patients 50-75 years of age.
- Smoking status and alcohol consumption, since both are modifiable contributors to fracture and cardiovascular risk.
Unexpected bleeding
Investigate any unexpected or unscheduled vaginal bleeding with endometrial sampling to rule out endometrial carcinoma — this applies whether or not the patient is using hormone therapy, and is never assumed to be simple breakthrough bleeding without assessment.[1]
Contraindications to hormone therapy
Confirm the absence of the following before initiating systemic estrogen or progestogen therapy:
| Hormone | Absolute contraindications |
|---|---|
| Estrogen | Undiagnosed vaginal bleeding; active liver disease; active thromboembolic disease; known or suspected breast cancer or other estrogen-sensitive tumour; known or suspected pregnancy. |
| Progestogen | Undiagnosed vaginal bleeding; known or suspected breast cancer; known or suspected pregnancy. |
The risk of breast cancer or thromboembolism recurrence after starting estrogen in a patient with a personal history of either is not well established, and caution is warranted in patients with existing cardiovascular disease; the benefit-risk balance must be individualized for every candidate.[1]
Treatment Targets
- Reduce the frequency and severity of vasomotor symptoms (hot flashes, night sweats) to a level that no longer disrupts sleep, mood, or daily function.
- Resolve or prevent progression of genitourinary syndrome of menopause symptoms — vaginal dryness, dyspareunia, and related urinary symptoms.
- Support sleep quality and mood stability through the menopausal transition.
- Preserve bone mineral density and reduce fracture risk in patients for whom hormone therapy is also an appropriate osteoporosis strategy.
- In early or premature menopause, correct the cardiovascular and bone risk associated with an extended period of estrogen deficiency by treating until at least the average age of natural menopause (about 51).
- Use the lowest effective dose for the shortest duration needed to meet the patient's individual goals, reassessed at least annually.
Choose Initial Treatment
Is menopausal hormone therapy (MHT) appropriate?
MHT, 1st line for bothersome vasomotor symptoms in a patient under 60 years of age or within 10 years of the final menstrual period, once absolute contraindications are excluded — this is the single most effective treatment for vasomotor symptoms.[2]
Do not start MHT in a patient with a personal history of breast cancer or another estrogen-sensitive tumour, undiagnosed vaginal bleeding, active or past venous thromboembolism, active liver disease, or known/suspected pregnancy — move directly to non-hormonal options for vasomotor symptoms, and see the genitourinary-specific rule below if genitourinary symptoms are also present.
The timing hypothesis / window of opportunity
Cardiovascular risk-benefit favours starting MHT within 10 years of the final menstrual period or before age 60 — this is when the most favourable data exist and when trial and observational evidence together suggest a neutral-to-favourable cardiovascular effect. Do not newly initiate MHT for symptom control in a patient 10 or more years past menopause or 60 years of age or older — the risk-benefit balance is less favourable in this group, and non-hormonal options should be used instead.[2]
Uterine status determines the regimen
A patient with an intact uterus using any systemic (oral or transdermal) estrogen needs a progestogen added — continuously every day, or cyclically for 12-14 consecutive days each calendar month — to protect against endometrial hyperplasia; systemic estrogen must never be prescribed alone in this group, with the sole exceptions of the tissue-selective estrogen complex (conjugated estrogens/bazedoxifene) and tibolone, both of which provide their own endometrial protection.
A patient without a uterus (post-hysterectomy) uses estrogen alone, given continuously, with no added progestogen.
Route selection
Consider transdermal estrogen preferentially over oral in patients with additional venous thromboembolism risk factors, migraine, high triglycerides, hypertension, malabsorption, low libido, or who smoke or work rotating shifts — the transdermal route avoids first-pass hepatic metabolism and, based on observational data, carries a lower venous thromboembolism signal than oral estrogen at equivalent doses.[1]
Genitourinary symptoms specifically
Local vaginal estrogen, 1st line for GSM when genitourinary symptoms are the only or the dominant complaint — it works with minimal systemic absorption, does not require an added progestogen at recommended doses even with an intact uterus, and can be considered even when systemic MHT is contraindicated for reasons other than active breast cancer, since systemic exposure is minimal; add it to systemic MHT if genitourinary symptoms persist despite otherwise-effective systemic therapy.[3]
Perimenopausal patients needing contraception
Offer combined hormonal contraceptives or the levonorgestrel-releasing intrauterine system combined with estrogen as alternatives to standard MHT in a perimenopausal patient who also needs contraception or control of irregular/heavy bleeding — standard low-to-standard-dose MHT does not provide reliable contraception.
Non-Pharmacologic Treatment
- Cooling measures (dressing in layers, fans, lowering ambient temperature) and avoiding individual triggers (spicy food, hot drinks, caffeine, alcohol) are not harmful and can be tried, though clinical evidence of benefit for vasomotor symptoms is limited.
- Weight loss and a dietary pattern lower in fat and higher in fruit, vegetables, and whole grains may reduce vasomotor symptoms in patients who are overweight.
- Smoking cessation reduces vasomotor symptom frequency/severity and independently reduces cardiovascular and fracture risk — counsel on cessation at every visit regardless of hormone therapy status.
- Regular exercise (at least 150 minutes per week of moderate intensity) is recommended for mood, cardiovascular risk, and bone health, even though exercise and yoga have not been shown to directly reduce vasomotor symptom frequency compared with placebo.
- Cognitive behavioural therapy (CBT) — a structured, short-term psychotherapy — reduces how bothersome vasomotor symptoms are and improves coping, sleep, and mood; effective in both group and self-help formats, and a reasonable option regardless of hormone therapy status.
- Clinical hypnosis has shown benefit for vasomotor symptom frequency in small trials.
- Acupuncture has inconsistent trial results and should not be presented as a reliably effective option.
- For genitourinary symptoms: regular use (at least twice weekly) of a non-hormonal vaginal moisturizer provides longer-lasting relief of dryness than an as-needed lubricant, and a vaginal lubricant used at the time of intercourse reduces dyspareunia — either can be used alone for mild symptoms or alongside local vaginal estrogen for more significant symptoms.
Special Populations
Pregnancy
Menopausal hormone therapy is not indicated in pregnancy; a perimenopausal patient can still conceive and needs reliable contraception if pregnancy is not desired — standard low-to-standard-dose MHT does not reliably prevent pregnancy, so a perimenopausal patient requiring contraception should use a combined hormonal contraceptive or the levonorgestrel-releasing intrauterine system instead of, or alongside, symptom-focused therapy.
Breastfeeding
Menopausal hormone therapy is not a relevant consideration during lactation, since this is a premenopausal physiologic state; estrogen-containing therapy used for another indication in this context can reduce milk supply.
Early and premature menopause
Offer MHT to patients who enter menopause early (before 45) or prematurely (before 40), since the extended duration of estrogen deficiency is associated with an earlier rise in cardiovascular disease and osteoporosis risk than in patients reaching menopause at the average age. Continue treatment until at least the average age of natural menopause (about 51) rather than stopping after a fixed short course, using standard or higher-than-standard estrogen doses as needed for adequate physiologic replacement.[1]
Breast cancer history
Systemic MHT is avoided in patients with a personal history of breast cancer — use non-hormonal options (an SSRI/SNRI, gabapentin, or fezolinetant) for vasomotor symptoms first. For genitourinary symptoms that do not respond to non-hormonal measures (moisturizers, lubricants), low-dose vaginal estrogen may be considered on an individualized basis with oncologist involvement, including in patients on tamoxifen; evidence specifically in patients on an aromatase inhibitor is more limited, since that class's treatment goal is complete suppression of tissue-level estrogen, so vaginal estrogen is generally avoided in that combination without oncology input.[3]
Tamoxifen users specifically
Avoid paroxetine and fluoxetine in patients taking tamoxifen — both are strong CYP2D6 inhibitors that reduce conversion of tamoxifen to its active metabolite, endoxifen. Escitalopram, citalopram, venlafaxine, desvenlafaxine, and gabapentin do not share this interaction and are preferred non-hormonal options in this group.
BRCA carriers after risk-reducing surgery
MHT after risk-reducing bilateral salpingo-oophorectomy does not appear to negate the protective benefit of the surgery and is a reasonable option to bridge such patients to the average age of natural menopause, in the absence of a personal breast cancer history.
Renal and hepatic impairment
Active liver disease is an absolute contraindication to systemic estrogen. Fezolinetant is contraindicated in cirrhosis and in severe renal impairment or end-stage renal disease, and requires baseline and periodic liver enzyme monitoring regardless of baseline hepatic status.[6]
Bone health
Menopausal hormone therapy is a reasonable first-line option for osteoporosis prevention specifically in a patient who also has bothersome vasomotor symptoms and desires treatment for both; it is not the preferred first-line osteoporosis therapy in a patient without vasomotor symptoms, where a bisphosphonate or denosumab is generally preferred instead (see Drug Tables for dosing — comprehensive fracture-risk-stratified osteoporosis pharmacotherapy selection is covered in dedicated osteoporosis-specific clinical guidance).[7]
Counsel adequate calcium intake (dietary sources preferred, targeting approximately 1200 mg/day from diet and supplementation combined) and vitamin D — current Canadian guidance recommends 400 IU daily for adults over 50 from diet and supplementation combined, individualized upward only for patients at risk of deficiency, superseding the older blanket 800-2000 IU/day recommendation.[7]
Monitoring & Follow-Up
Reassess vasomotor symptom control and adjust the estrogen dose after 3-4 weeks of therapy at standard starting doses; lower starting doses may need 8-12 weeks before their full effect is apparent, so avoid escalating too early in that situation. Review the ongoing need for MHT with the patient at least annually, weighing continued symptom benefit against risk factors that may have changed (new cardiovascular risk factors, new breast findings, age crossing further past the window of opportunity). Investigate any unscheduled or unexpected vaginal bleeding promptly at any point during therapy rather than assuming it is benign breakthrough bleeding. Continue routine breast examination and mammography screening per the standard schedule while on MHT, and check blood pressure at follow-up visits. In a patient using drospirenone-containing combined therapy, check serum potassium after the first treatment cycle if the patient has a risk factor for hyperkalemia (renal disease, concomitant ACE inhibitor/ARB, potassium-sparing diuretic, or NSAID use). In a patient using fezolinetant, obtain baseline ALT, AST, alkaline phosphatase, and bilirubin before starting, and monitor periodically thereafter; discontinue if ALT or AST reaches 2 times the upper limit of normal, or bilirubin reaches 2 times the upper limit of normal.[6] Reassess bone mineral density per the individual patient's osteoporosis risk profile. When stopping MHT, gradual dose tapering is reasonable if it helps the patient, though evidence has not shown that tapering changes the likelihood or timing of symptom recurrence compared with stopping abruptly — if symptoms return at a lower dose during a taper, continuing that dose until symptoms settle is a reasonable approach.
Common Errors to Avoid
- Prescribing systemic estrogen to a patient with an intact uterus without an added progestogen — with the specific exceptions of the tissue-selective estrogen complex (conjugated estrogens/bazedoxifene) and tibolone, both of which provide their own endometrial protection.
- Using topical or transdermal progesterone cream for endometrial protection — it has not been shown to provide adequate protection against endometrial hyperplasia and must not substitute for an oral or intrauterine progestogen.
- Defaulting to clonidine or pregabalin as first-line non-hormonal options out of habit — the current evidence-based position statement does not support either; use an SSRI/SNRI, gabapentin, oxybutynin, or fezolinetant instead.[5]
- Prescribing paroxetine or fluoxetine to a patient taking tamoxifen — strong CYP2D6 inhibition blunts conversion to the active metabolite, endoxifen.
- Newly initiating MHT purely for symptom control in a patient 10 or more years past menopause or 60 years of age or older — the cardiovascular risk-benefit balance is unfavourable outside the window of opportunity.
- Ordering FSH or estradiol levels to confirm menopause in a typical patient over 45 with 12 months of amenorrhea — unnecessary and does not change management.
- Assuming unscheduled or unexpected vaginal bleeding is simple breakthrough bleeding without investigating it.
- Withholding local vaginal estrogen from a patient with a history of breast cancer without first considering it, with oncologist involvement, when genitourinary symptoms have not responded to non-hormonal measures.
- Recommending natural health products such as black cohosh as an evidence-based alternative to established therapy — most have insufficient or negative evidence, and black cohosh specifically carries a hepatotoxicity signal.
- Treating vasomotor symptoms and genitourinary symptoms as the same problem — systemic therapy that controls hot flashes well may still leave genitourinary symptoms untreated, and local vaginal estrogen alone does not treat vasomotor symptoms.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation, including hepatic/renal adjustment where relevant. Every systemic estrogen row assumes a progestogen is added when the uterus is intact, unless stated otherwise. Select any drug name to open its complete Pharmasist Drug Database page.
Estrogens, oral
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Estradiol | Recommended starting dose: 0.5-1 mg PO once daily | Breakthrough bleeding/spotting, nausea, headache, bloating/water retention, breast tenderness | CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) lower levels; CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) raise levels | Add a progestogen if the uterus is intact. |
| Conjugated estrogens | Recommended starting dose: 0.3-0.625 mg PO once daily | Breakthrough bleeding/spotting, nausea, headache, bloating/water retention, breast tenderness | Same as estradiol | Add a progestogen if the uterus is intact. |
Estrogens, transdermal
The transdermal route avoids first-pass hepatic metabolism, giving less effect on triglycerides and, per observational data, a lower venous thromboembolism signal than oral estrogen at equivalent doses.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Estradiol, transdermal patch | Estradot: 25-50 mcg/day, applied twice weekly Climara: 25-100 mcg/day, applied once weekly | Application-site redness/irritation, breakthrough bleeding/spotting, nausea, headache, breast tenderness | Fewer clinically relevant hepatic interactions than oral estrogen given bypass of first-pass metabolism | Rotate application sites; avoid the breasts and waistline. May benefit patients who smoke, have malabsorption, high triglycerides, or low libido. |
| Estradiol, transdermal gel | Estrogel: 0.75-1.5 mg (1-2 actuations) once daily Divigel: 0.25-1 mg (1 packet) once daily | Application-site redness/irritation, breakthrough bleeding/spotting, nausea, headache, breast tenderness | Fewer clinically relevant hepatic interactions than oral estrogen given bypass of first-pass metabolism | Estrogel: apply to the arm or inner thigh, do not rotate site. Divigel: alternate right/left thigh with each dose; flammable until dry — avoid open flame near the site until it has dried. |
Estrogen-progestin combinations, oral
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Drospirenone / estradiol | Continuous: 1 tablet (1 mg estradiol/1 mg drospirenone) PO once daily | Breakthrough bleeding/spotting, nausea, headache, bloating, chloasma, mood changes, hyperkalemia | Additive hyperkalemia risk with ACE inhibitors, ARBs, potassium-sparing diuretics, or NSAIDs | Check potassium after the first cycle in patients at hyperkalemia risk. |
Estrogen-progestin combinations, transdermal
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Estradiol / norethindrone acetate | Twice weekly patch: 50 mcg estradiol/140-250 mcg norethindrone acetate per day | Application-site redness/irritation, breakthrough bleeding/spotting, chloasma, mood changes | Fewer clinically relevant hepatic interactions than oral combinations | Combined product avoids needing a separate progestogen prescription. |
Tissue selective estrogen complex (TSEC)
Bazedoxifene is a SERM that antagonizes estrogen receptors on endometrial/breast tissue while agonizing bone — it provides endometrial protection without an added progestogen.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Conjugated estrogens / bazedoxifene | Dosing: 1 tablet (0.45 mg conjugated estrogens/20 mg bazedoxifene) PO once daily | Breakthrough bleeding/spotting, nausea, bloating, chloasma | None significant | Alternative for a patient with an intact uterus who wants to avoid progestogen-related side effects (breast tenderness, mood changes). Not indicated for osteoporosis prevention despite reducing bone resorption. |
Hormone therapy — other
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Tibolone | Dosing: 2.5 mg PO once daily | Breakthrough bleeding/spotting, nausea, GI upset, fatigue, breast tenderness, bloating, increased appetite | None significant | Synthetic steroid metabolized to metabolites with combined weak estrogenic, progestogenic, and androgenic activity — no added progestogen needed. |
Progestogens, oral
Required alongside any systemic estrogen (except the TSEC and tibolone) in a patient with an intact uterus.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Medroxyprogesterone acetate | Cyclic: 5 mg PO once daily for the first 12 days of each month Continuous: 2.5 mg PO once daily | Bloating, irritability, mood swings, breast tenderness, headache, water retention, breakthrough bleeding | None significant | Continuous dosing prevents menstrual bleeding; cyclic dosing produces an expected withdrawal bleed. |
| Norethindrone acetate | Dosing: 5 mg PO once daily | Bloating, irritability, mood swings, breast tenderness, headache, water retention, breakthrough bleeding | None significant | Alternative oral progestogen. |
| Progesterone, micronized | Cyclic: 200 mg PO at bedtime for 12-14 days each month Continuous: 100 mg PO at bedtime | Bloating, irritability, mood swings, breast tenderness, headache, water retention, breakthrough bleeding, drowsiness | None significant | Contains soy lecithin — caution with soy allergy. Take at bedtime given sedating effect. |
Progestins, intrauterine
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Levonorgestrel-releasing intrauterine system | Endometrial protection (off-label): 52 mg IUS inserted once, replaced every 5 years | Irregular spotting (especially first 3-6 months), ovarian cysts, insertion-related pain, mood changes | Predominantly local mechanism, so hepatic enzyme-inducing drugs do not reduce efficacy the way they can with systemic hormonal contraceptives | Off-label for endometrial protection during estrogen therapy — not a Health-Canada-approved indication for this specific use, though trial data support endometrial protection for up to 5 years. |
Non-hormonal — SSRIs and SNRIs
Onset within about 2 weeks; higher doses do not add vasomotor benefit but do add side effects.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Venlafaxine | Dosing: Start 37.5 mg PO once daily, increase to 75 mg once daily after 1 week if needed | GI upset, dry mouth, drowsiness, nervousness, sexual dysfunction | Caution with other serotonergic agents (serotonin syndrome risk) | 1st-line non-hormonal option, particularly with concurrent mood/anxiety symptoms. Taper when stopping. |
| Desvenlafaxine | Dosing: 50-100 mg PO once daily | GI upset, dry mouth, drowsiness, nervousness, sexual dysfunction | Caution with other serotonergic agents | Alternative SNRI. Taper when stopping. |
| Escitalopram | Dosing: 10-20 mg PO once daily | GI upset, insomnia or somnolence, sexual dysfunction, SIADH with hyponatremia (uncommon) | No clinically significant CYP2D6 inhibition | Preferred SSRI in patients taking tamoxifen, since it does not blunt tamoxifen's active metabolite. |
| Citalopram | Dosing: 10-20 mg PO once daily | GI upset, insomnia or somnolence, sexual dysfunction, SIADH with hyponatremia (uncommon) | No clinically significant CYP2D6 inhibition | Alternative SSRI, similar profile to escitalopram. |
| Paroxetine | IR: 10-20 mg PO once daily CR: 12.5-25 mg PO once daily | GI upset, sexual dysfunction, discontinuation symptoms if stopped abruptly | Strong CYP2D6 inhibitor — reduces conversion of tamoxifen to its active metabolite, endoxifen | Avoid in patients taking tamoxifen. |
Non-hormonal — gabapentinoids
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Gabapentin | Titration: Start 300 mg PO at bedtime, increase over 3-7 days to 300 mg PO TID Alternative regimen: 600-900 mg PO once nightly | Somnolence, dizziness | None significant | Current evidence supports gabapentin, particularly for night-predominant symptoms given its sedating effect. Taper over about 1 week when stopping. |
| Pregabalin | Dosing: 150-300 mg PO daily in divided doses | Somnolence, dizziness | None significant | Not recommended in the current evidence-based position statement for vasomotor symptoms despite earlier positive trial data — use gabapentin instead. |
Non-hormonal — neurokinin-3 (NK3) receptor antagonist
The newest non-hormonal class; requires liver-enzyme monitoring given a measurable transaminase-elevation signal in trials.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Fezolinetant | Dosing: 45 mg PO once daily | Elevated ALT/AST, GI upset, insomnia, back pain | Contraindicated with moderate/strong CYP1A2 inhibitors (e.g., fluvoxamine, mexiletine) — significantly raises fezolinetant exposure | Obtain baseline ALT/AST/alkaline phosphatase/bilirubin before starting; do not start if ALT or AST is 2x ULN or higher. Monitor periodically. Contraindicated in cirrhosis or severe renal impairment/ESRD. |
Non-hormonal — other
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Oxybutynin, immediate-release | Dosing: 2.5-5 mg PO BID | Dry mouth, constipation, tachycardia (anticholinergic effects) | Additive anticholinergic burden with other anticholinergic drugs | Current evidence supports oxybutynin. Use with caution in renal impairment. |
| Oxybutynin, extended-release | Dosing: 15 mg PO once daily | Dry mouth, constipation, tachycardia (anticholinergic effects) | Additive anticholinergic burden with other anticholinergic drugs | Use with caution in renal impairment and in older adults given anticholinergic burden. |
| Clonidine | Dosing: 0.05 mg PO BID | Dizziness, dry mouth, drowsiness, constipation, hypotension | Additive hypotension with other antihypertensives | Not recommended in the current evidence-based position statement given limited effectiveness and tolerability. |
Local vaginal estrogen
Minimal systemic absorption at recommended doses — no added progestogen needed even with an intact uterus.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Estradiol, vaginal ring | Estring: 1 ring PV, replaced every 3 months | Local burning/irritation, vaginal discharge/leakage | None significant at recommended doses | Insert into the upper third of the vagina; can be inserted/removed by the patient. |
| Estradiol, vaginal tablet | Vagifem 10: 1 insert PV once daily for 2 weeks, then twice weekly | Local burning/irritation, vaginal discharge | None significant at recommended doses | Insert with the supplied applicator. |
| Conjugated estrogens, vaginal cream | Induction: 0.5 g (0.3 mg) PV once daily for 14 days Maintenance: 0.5 g (0.3 mg) PV 2-3 times weekly | Local burning/irritation, vaginal discharge/leakage | None significant at recommended doses | Oil-based — may weaken latex condoms/diaphragms during use. |
| Estrone vaginal cream | Cyclic regimen: 0.5-4 g (0.5-4 mg) PV daily, 3 weeks on/1 week off Continuous regimen: 0.5-4 g (0.5-4 mg) PV 2-3 times weekly | Local burning/irritation, vaginal discharge/leakage | None significant at recommended doses | A less commonly used local option (a different molecule — estrone rather than estradiol or conjugated estrogens). Intended for short-term use per product labelling. |
Vaginal DHEA
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Prasterone | Dosing: 1 insert (6.5 mg) PV once daily at bedtime | Vaginal discharge, abnormal local cytology finding | None significant | Converted to estrogen and androgen locally within vaginal tissue (intracrinology) with minimal systemic absorption. |
Oral SERM for genitourinary symptoms
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ospemifene | Dosing: 60 mg PO once daily with food | Hot flashes (can worsen vasomotor symptoms), leg cramps, hyperhidrosis | None significant | A systemic oral option for dyspareunia due to GSM when local therapy is not preferred or tolerated. Contraindicated with undiagnosed vaginal bleeding or known/suspected estrogen-dependent neoplasia. |
Vaginal moisturizers and lubricants
Non-hormonal first step for genitourinary symptoms; can be used alone for mild symptoms or alongside any hormonal option for more significant symptoms.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Polycarbophil vaginal gel | Maintenance: 1 applicatorful PV 2-3 times weekly | Local irritation, discharge | None significant | Regular (not as-needed) use provides longer-lasting relief than a lubricant. No Pharmasist Drug Database monograph exists for this OTC vaginal-gel product (a different formulation from oral calcium polycarbophil fibre supplements). |
| Vaginal hyaluronic acid gel | Maintenance: Per product instructions, typically 2-3 times weekly after an initial daily loading period | Local irritation | None significant | An alternative non-hormonal moisturizer; no Pharmasist Drug Database monograph exists for this OTC product. |
| Vaginal lubricant (water- or silicone-based) | As needed: Apply at the time of intercourse | Local irritation (uncommon) | Oil-based lubricants can weaken latex condoms — use water- or silicone-based products with latex barriers | As-needed relief of dyspareunia; does not provide the longer-lasting relief of a regular moisturizer or local estrogen. |
Bone health adjuncts
Menopausal hormone therapy is a reasonable first-line osteoporosis option specifically when vasomotor symptoms are also present and treatment is desired for both; otherwise a bisphosphonate or denosumab is generally preferred (comprehensive fracture-risk-stratified selection is covered in dedicated osteoporosis-specific guidance).
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Calcium carbonate | Dosing: Individualized, in divided doses with meals | Constipation, bloating | Reduces absorption of levothyroxine, tetracyclines, fluoroquinolones, and bisphosphonates if taken together — separate dosing by at least 2 hours | Individualize total intake (diet plus supplementation) to approximately 1200 mg/day elemental calcium. |
| Vitamin D3 (cholecalciferol) | Adults over 50: 400 IU PO once daily from diet and supplementation combined, individualized upward if at risk of deficiency | Generally well tolerated; hypercalcemia with excessive doses | None significant at standard doses | Current Canadian guidance lowered the routine recommendation from the older 800-2000 IU/day figure. |
| Alendronate | Osteoporosis treatment: 70 mg PO once weekly | Esophageal irritation, GI upset, rare osteonecrosis of the jaw or atypical femur fracture with long-term use | Reduced absorption with calcium, iron, antacids, and food — separate dosing | Take first thing in the morning on an empty stomach with a full glass of water; remain upright for at least 30 minutes. |
| Denosumab | Osteoporosis treatment: 60 mg SC once every 6 months | Hypocalcemia, skin infection (cellulitis), rare osteonecrosis of the jaw or atypical femur fracture | None significant | Ensure adequate calcium/vitamin D intake before dosing given hypocalcemia risk. Rebound fracture risk after stopping — bridge with a bisphosphonate if discontinuing. |
| Raloxifene | Osteoporosis treatment: 60 mg PO once daily | Hot flashes, leg cramps, increased venous thromboembolism risk | None significant | A SERM for osteoporosis prevention/treatment — not used for vasomotor symptoms, since it can worsen hot flashes; avoid when vasomotor symptoms are the primary complaint. |
References
- Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine, Nutrition, and Lifestyle — Journal of Obstetrics and Gynaecology Canada, Society of Obstetricians and Gynaecologists of Canada (Yuksel N, Evaniuk D, Huang L, et al.). J Obstet Gynaecol Can 2021;43(10):1188-1204
- The 2022 hormone therapy position statement of The North American Menopause Society — The Menopause Society (formerly the North American Menopause Society). Menopause 2022;29(7):767-794
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society — The Menopause Society (formerly the North American Menopause Society). Menopause 2020;27(9):976-992
- Guideline No. 422b: Menopause and Genitourinary Health — Journal of Obstetrics and Gynaecology Canada, Society of Obstetricians and Gynaecologists of Canada (Johnston S, Bouchard C, Fortier M, Wolfman W). J Obstet Gynaecol Can 2021;43(11):1301-1307.e1
- The 2023 nonhormone therapy position statement of The North American Menopause Society — The Menopause Society (formerly the North American Menopause Society). Menopause 2023;30(6):573-590
- Summary Basis of Decision — VEOZAH (fezolinetant) — Health Canada, Drug and Health Products Portal. Approved December 2, 2024
- Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update — Canadian Medical Association Journal, Osteoporosis Canada (Morin SN, Feldman S, Funnell L, et al.). CMAJ 2023;195(39):E1333-E1348
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.